Ionis Provides Update on Development Program Evaluating PCSK9 Antisense Drug for the Treatment of Hypercholesterolemia

Ionis Provides Update on Development Program Evaluating PCSK9 Antisense Drug for the Treatment of Hypercholesterolemia

ION449 (AZD8233) met the primary endpoint in phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not proceed to Phase 3 development based on predefined criteria CARLSBAD, Calif., September 23, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that key results from the 2b SOLANO A study in patients with hypercholesterolemia demonstrated …

Ionis Provides Update on Development Program Evaluating PCSK9 Antisense Drug for the Treatment of Hypercholesterolemia Read More »